Universität zu Köln

Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J. and Loibl, S. (2021). Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Ann. Oncol., 32. S. S443 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Full text not available from this repository.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Marme, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hanusch, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Furlanetto, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Denkert, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Link, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Untch, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Blohmer, J-U. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jackisch, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reinisch, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rhiem, K. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schneeweiss, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Solbach, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schoellhorn, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fasching, P. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rey, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Loibl, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-603407
DOI:	10.1016/j.annonc.2021.08.480
Journal or Publication Title:	Ann. Oncol.
Volume:	32
Page Range:	S. S443 - 2
Date:	2021
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	1569-8041
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/60340